Merdad Parsey Gilead Sciences, Inc. (GILD) insider trading activity

Merdad Parsey is Chief Medical Officer of GILEAD SCIENCES, INC.. Currently has a direct ownership of 96,380 shares of GILD, which is worth approximately $7.59 Million. The most recent transaction as insider was on Dec 30, 2022, when has been sold 553 shares (Common Stock) at a price of $85.33 per share, resulting in proceeds of $47,187. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 96.4K

0.08% 3M change

227.8% 12M change

Total Value Held $7.59 Million

Merdad Parsey Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Dec 30 2022	SELL Open market or private sale	$47,187 $85.33 p/Share	553 Reduced 1.2%	45,556 Common Stock
Dec 10 2022	SELL Payment of exercise price or tax liability	$42,753 $87.97 p/Share	486 Reduced 1.04%	46,109 Common Stock
Dec 10 2022	BUY Exercise of conversion of derivative security	-	1,039 Added 2.18%	46,595 Common Stock
Nov 10 2022	SELL Payment of exercise price or tax liability	$187,336 $82.6 p/Share	2,268 Reduced 4.74%	45,556 Common Stock
Nov 10 2022	BUY Exercise of conversion of derivative security	-	5,099 Added 9.63%	47,824 Common Stock
Sep 10 2022	SELL Payment of exercise price or tax liability	$31,400 $65.28 p/Share	481 Reduced 1.11%	42,725 Common Stock
Sep 10 2022	BUY Exercise of conversion of derivative security	-	1,039 Added 2.35%	43,206 Common Stock
Jun 10 2022	SELL Payment of exercise price or tax liability	$29,459 $60.74 p/Share	485 Reduced 1.14%	42,167 Common Stock
Jun 10 2022	BUY Exercise of conversion of derivative security	-	1,039 Added 2.38%	42,652 Common Stock
Mar 10 2022	SELL Payment of exercise price or tax liability	$203,010 $57.92 p/Share	3,505 Reduced 7.83%	41,265 Common Stock
Mar 10 2022	BUY Exercise of conversion of derivative security	-	7,612 Added 14.53%	44,770 Common Stock
Feb 15 2022	BUY Grant, award, or other acquisition	$18,141 $52.13 p/Share	348 Added 0.83%	41,613 Common Stock
Jan 26 2022	BUY Grant, award, or other acquisition	-	20,298 Added 35.33%	37,158 Common Stock
Nov 10 2021	SELL Payment of exercise price or tax liability	$156,182 $67.32 p/Share	2,320 Reduced 12.1%	16,860 Common Stock
Nov 10 2021	BUY Exercise of conversion of derivative security	-	5,100 Added 21.0%	19,180 Common Stock
Aug 15 2021	BUY Grant, award, or other acquisition	$55 $55.08 p/Share	1 Added 0.01%	14,080 Common Stock
Mar 10 2021	SELL Payment of exercise price or tax liability	$104,748 $63.91 p/Share	1,639 Reduced 10.43%	14,079 Common Stock
Mar 10 2021	BUY Exercise of conversion of derivative security	-	3,455 Added 18.02%	15,718 Common Stock
Feb 15 2021	BUY Grant, award, or other acquisition	$20,697 $56.86 p/Share	364 Added 2.88%	12,263 Common Stock
Jan 26 2021	BUY Grant, award, or other acquisition	-	9,214 Added 43.64%	11,899 Common Stock
Nov 10 2020	SELL Payment of exercise price or tax liability	$146,458 $60.62 p/Share	2,416 Reduced 47.36%	2,685 Common Stock
Nov 10 2020	BUY Exercise of conversion of derivative security	-	5,101 Added 50.0%	5,101 Common Stock

Also insider at

SGMT

Sagimet Biosciences Inc.

Director

Merdad Parsey

Chief Medical Officer

Foster City, CA

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells GILD shares.

Notify only if

Value

Insider Trading

Get notified when an Gilead Sciences, Inc. insider buys or sells GILD shares.

Notify only if

Operation

Value

Type

News

Receive news related to GILEAD SCIENCES, INC.

Track Activities on GILD

Account